AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
LEO Pharma has 9.7 points less BS than the average for Medical Devices, Pharma & Biotech.
Medical Devices, Pharma & Biotech BS: LEO Pharma (skinoren.com)
This is a high-substance corporate pharmaceutical site that uses fluff as a wrapper for hard clinical and financial data. While the headers are poetic and generic, the underlying evidence is forensic, dated, and highly auditable. The low BS score reflects a professional organization that backs its global leader claims with multi-billion dollar revenue figures and specific FDA milestones.
Replace fluff-heavy H1 and H4 headings with more descriptive, noun-based headers that highlight specific therapeutic areas or milestones. Implement Organization and MedicalOrganization schema with sameAs links to the LEO Foundation and executive LinkedIn profiles to close the authority gap. Add direct outbound links to ClinicalTrials.gov or PubMed for every drug mention in the innovation highlights section. Remove the repetitive making a fundamental difference phrase and replace it with more specific positioning regarding their focus on medical dermatology.
The site exhibits a dual personality in information density. Headings are heavily saturated with power words like revolutionary, innovative, and fundamental difference (e.g., [H1] Together, we reach far beyond the skin), which score high for fluff. However, the body substance ratio is exceptionally high, particularly on the annual reporting page, which cites specific revenue figures (DKK 13,499 million), market-specific growth (+35% in North America), and named product launches like Anzupgo and Spevigo. Specificity is abundant with over 10 instances of exact dates, therapeutic targets, and financial outcomes across the four pages analyzed.
Most sites "have schema," but AI still cannot understand what their pages represent. Run a Structured Data AI Audit to see what entity types your pages actually resolve into.
There is very little semantic drift between the high-level brand promises and the sub-page evidence. The homepage H1 promises to reach beyond the skin, and the sub-pages deliver by detailing systemic treatments for complex conditions like generalized pustular psoriasis. The financial highlights and innovation highlights sub-sections directly support the homepage claim of being a global leader in medical dermatology. Consistency is maintained across pages regarding the 2025/2026 strategic transformation and revenue targets.
Stop the ROI leak caused by technical debt and strategic misalignment. Conduct an Independent Strategic Diagnosis for 1 Euro to identify high impact issues across all audit categories.
While the review_count of 8 on the annual reporting page is likely a metadata artifact rather than consumer reviews, the site avoids typical trust theatre traps. Claims such as serving close to 100 million patients are substantiated by a century of experience and a listed portfolio of established brands. There is a clear proof path provided through a 10-year archive of annual reports and sustainability statements (2015-2025), though the site lacks direct outbound links to peer-reviewed study DOIs on these specific pages.
Proof density is high, with a significant ratio of verifiable evidence to vague assertions. The site lists a decade of archived reports, specific manufacturing country-level environmental data, and partnership details with Gilead Sciences. Unlike low-substance sites, LEO Pharma provides granular engagement structures by separating media inquiries, product complaints, and drug safety reporting (pharmacovigilance).
To see how the system reconstructs a medical entity graph at scale, review the full Cleveland Clinic Structured Data audit. View the Cleveland Clinic Structured Data Audit for a live example of identity level decomposition and cross page entity mapping.
The site suffers from high industry cliché density in its marketing copy, utilizing phrases like advancing human health and breakthrough medicines frequently. The value proposition of making a fundamental difference is generic enough to be copy-pasted onto any Tier 1 pharma competitor. However, the template language is salvaged by the inclusion of highly specific technical details regarding the STAT6 program and IL-36RA biologics, which prevents the sections from being purely boilerplate.
There is a notable gap in structured data; the schema_json only identifies the entity as a WebSite rather than an Organization or MedicalBusiness, which would be expected for a global pharmaceutical leader. While the CEO Christophe Bourdon and key media heads are named, they lack associated Person schema or sameAs links to verify their professional footprints directly from the page metadata. Technical implementation of the heading hierarchy is clean, which supports corporate credibility.
The marketing tone is aspirational, but the disconnect is minimal because the performance claims are paired with auditable financial results. For example, the claim of delivering robust revenue growth is immediately followed by the 9% CER figure for Q1 2026. The site avoids making efficacy claims without referencing the specific regulatory context, such as mentioning the FDA approval in July 2025 for Anzupgo cream.
Medical Devices, Pharma & Biotech BS: LEO Pharma (skinoren.com)
The content perfectly aligns with the Medical Devices, Pharma & Biotech category. It utilizes precise industry-standard financial metrics like CER (Constant Exchange Rates) and EBITDA, alongside clinical terminology such as pan-JAK inhibitor, IL-36RA biologic, and Phase 3 trials.
Every pillar of machine readability depends on one foundation: explicit, verifiable entity definitions. Explore the Structured Data Technical Framework to understand how identity, relationships, and @id anchors form the base layer of AI interpretation.
“The score of 31 is primarily driven by Commodity Fingerprint and Information Density (specifically heading fluff). The high volume of specific financial data and the presence of a 10-year report archive significantly suppressed the score in the Trust and Proof pillar. The technical credibility and cross-page consistency are high, resulting in a very low Semantic Coherence penalty.”
Analysis Disclosure & Source Attribution
Snapshot Date: June 19, 2026
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to see how machine logic interprets digital signals.
Machine Perception Notice: This evaluation is generated by machine-read logic (MRL). The AI interprets the “Digital Ghost” of a website (code, metadata, and semantic structures), which may differ from what a human sees at the same moment. This is an automated technical diagnostic and not a statement of fact or human opinion regarding the real-world integrity or legitimacy of the business. Any missing or inaccessible elements in the snapshot are treated as machine-read signals, reflecting AI rendering limitations rather than intentional omission.
Notice to the Evaluated Business: This analysis is part of a non-adversarial audit. The results are intended as professional feedback to help improve machine-readability and authority signals. Any company can use these insights for free. When content is updated, a fresh audit can be requested at any time to reflect the current state.
To All Users: You are encouraged to visit the live site at LEO Pharma to view the most current version of their content and see directly what the company offers.